All In Biotech

Drug Trial Radar · NCT04775082

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

82

Actual

Start

Mar 4, 2021

Primary completion

Aug 1, 2023

Study completion Feb 8, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

Conditions

  • Obesity

Interventions

  • LiraglutideDrug

    The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. The dose will increase each week over 4 or 5 weeks until the final dose is reached.

  • PlaceboDrug

    The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Change in Body Mass Index (BMI)Time frame: Baseline (week 0), week 56

Locations

32 sites in 9 countries. Site status is shown where the registry gives one.

  • TMC Hlthcr Clin Res Office

    Tucson, Arizona

  • Children's Hospital Colorado

    Denver, Colorado

  • Solaris Clinical Research

    Meridian, Idaho

  • Pennington Biom Res Ctr

    Baton Rouge, Louisiana

  • Barry J. Reiner, MD LLC

    Baltimore, Maryland

  • University of Minnesota_CPOM

    Minneapolis, Minnesota

  • UBMD Peds-Div of Endo/Diabetes

    Buffalo, New York

  • PriMed Clinical Research

    Dayton, Ohio

  • UPMC Child Hosp-Pittsburgh

    Pittsburgh, Pennsylvania

  • UZ Brussel

    Brussels, Belgium

  • UZ Leuven - Kindergeneeskunde

    Leuven, Belgium

  • Mamc & Lnjp

    New Delhi, India

  • Endolife Specialty Hospitals

    Guntur, Andhra Pradesh, India

  • Rambam MC - Department of Pediatrics A

    Haifa, Israel

  • Schneider MC - Endrocrinology and Diabetes

    Petah Tikva, Israel

  • Hospital Putrajaya

    Putrajaya, Malaysia

  • University Malaya Medical Centre

    Lembah Pantai, Kuala Lumpur, Malaysia

  • Consultorio de Endocrinología y Pediatría

    Puebla City, Mexico

  • Hospital da Luz Lisboa, S.A.

    Lisbon, Portugal

  • Hospital da Luz

    Lisbon, Portugal

  • Centro Hospitalar Lisboa Norte

    Lisbon, Portugal

  • Unidade De Santa Maria E.P.E. - Hospital de Santa Maria

    Lisbon, Portugal

  • ULS De Santo António, E.P.E. - Hospital de Santo António

    Porto, Portugal

  • Unidade Local de Saúde de Santo António, E.P.E

    Porto, Portugal

  • CUF-Porto

    Porto, Portugal

  • Hospital CUF Porto S.A.

    Porto, Portugal

  • FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia

    Moscow, Russia

  • NSMU paediatric clinic

    Novosibirsk, Russia

  • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova

    Samara, Russia

  • Siberian State Medical University

    Tomsk, Russia

  • Kantonsspital Olten

    Olten, Switzerland

  • Kinderspital Endokrinologie, Zürich

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.